
KOD Stock Forecast & Price Target
KOD Analyst Ratings
Bulls say
Kodiak Sciences is a biopharmaceutical company with a promising pipeline of retinal medicines built on its proprietary Antibody Biopolymer Conjugate (ABC) platform. The company recently reported strong results in its GLOW2 study for tarcocimab tedromer (Zenkuda) in patients with non-proliferative diabetic retinopathy, supporting its multi-indication BLA filing. The company's other investigational medicines, KSI-501 and KSI-101, also show potential in treating retinal vascular diseases and have upcoming pivotal data readouts. While there are risks to the achievement of the target price, including competition and platform risks, we maintain a positive outlook on Kodiak Sciences based on its innovative platform and potential for strong financial performance in the future.
Bears say
Kodiak Sciences is currently facing a number of potential risks, including delays in regulatory approvals, competition from other innovative products in development, and the need for additional funding. Despite the positive Phase 3 GLOW2 results and potential for their ABC platform to address current anti-VEGF limitations, the company's outlook may be hindered by binary risks surrounding future datasets and the possibility for delays or setbacks in development. Additionally, there is a growing market for retinal medicine with emerging competition, which may impact Kodiak's potential for long-term profitability.
This aggregate rating is based on analysts' research of Kodiak Sciences Inc and is not a guaranteed prediction by Public.com or investment advice.
KOD Analyst Forecast & Price Prediction
Start investing in KOD
Order type
Buy in
Order amount
Est. shares
0 shares